Franco Nev Corp (FNV) 40.92 $FNV Franco-Nevada Shares

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Franco Nev Corp (FNV) 40.92 $FNV

Franco-Nevada Shares Down 19.7% Since SmarTrend's Sell Call (FNV)
Comtex SmarTrend(R) - Tue Jul 21, 12:20PM CDT
SmarTrend identified a Downtrend for Franco-Nevada (NYSE:FNV) on May 27th, 2015 at $51.07. In approximately 2 months, Franco-Nevada has returned 19.74% as of today's recent price of $40.99.
FNV: 40.92 (+0.19)

Shares of FNV Down 11.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Jul 14, 10:06AM CDT
SmarTrend identified a Downtrend for Franco-Nevada (NYSE:FNV) on May 27th, 2015 at $51.07. In approximately 2 months, Franco-Nevada has returned 10.98% as of today's recent price of $45.46.
FNV: 40.92 (+0.19)

Adrian Day's Embarrassment Of Riches: Gold Companies Cheap To Buy But Not For Long
The Gold Report - at Seeking Alpha - Sat Jul 04, 2:59AM CDT
Fund Manager Adrian Day believes that the U.S. dollar is fundamentally overvalued and we can expect a devaluation at some point. This is good news for the price of gold. In this interview with The Gold Report , Day adds the even-better news for...
BTG: 1.12 (+0.05), EGO: 3.21 (unch), FNV: 40.92 (+0.19), RGLD: 50.58 (+0.40), TAHO: 8.19 (+0.11), PVG: 4.73 (+0.10), GG: 12.75 (+0.14)

Franco-Nevada To Release Second Quarter 2015 Results
CNW Group - Thu Jun 25, 3:30PM CDT
Webcast: A live audio webcast will be accessible at www.franco-nevada.com
FNV.TO: 52.91 (-0.15), FNV: 40.92 (+0.19)

Upgrade Alert for Franco-Nevada (FNV)
Comtex SmarTrend(R) - Thu Jun 25, 7:18AM CDT
Franco-Nevada (NYSE:FNV) was upgraded from Market Perform to Outperform at Raymond James today. The stock closed yesterday at $48.93 on volume of 573,000 shares, below average daily volume of 628,000. Franco-Nevada has overhead space with shares priced $48.93, or 17.1% below the average consensus analyst price target of $59.06. Franco-Nevada shares should first meet resistance at the 50-day moving average (MA) of $51.08 and find additional resistance at the 200-day MA of $51.23.
FNV: 40.92 (+0.19)

Franco-Nevada Didn't Fall, Despite Low Oil Prices
Lior Cohen - at Seeking Alpha - Tue Jun 16, 3:13PM CDT

FNV: 40.92 (+0.19)

Franco-Nevada Back In Target Buying Range
Simit Patel - at Seeking Alpha - Mon Jun 15, 1:35AM CDT

FNV: 40.92 (+0.19)

Franco-Nevada Is The Best Gold Company Ever Created And Investors Should Sell It
SomaBull - at Seeking Alpha - Sat Jun 13, 3:28PM CDT

FNV: 40.92 (+0.19)

There Are Way Too Many Gold Companies In The World
SomaBull - at Seeking Alpha - Wed Jun 10, 10:16AM CDT

AAU: 0.61 (+0.03), RBY: 0.84 (-0.01), ABX: 6.93 (+0.03), AUQ: 2.86 (+0.10), AU: 6.37 (+0.01), NEM: 17.53 (+0.31), GFI: 2.78 (-0.10), IAG: 1.40 (+0.06), PVG: 4.73 (+0.10), NG: 3.10 (+0.10), HMY: 1.04 (unch), EGO: 3.21 (unch), KGC: 1.72 (+0.04), FNV: 40.92 (+0.19), NGD: 2.13 (+0.01), AGI: 3.18 (+0.16), CDE: 3.75 (-0.03), AUY: 2.01 (+0.06), GG: 12.75 (+0.14)

True Gold Mining Resumes Construction At Karma; Shares Have Considerable Upside
Hard Asset Investments - at Seeking Alpha - Tue Jun 09, 8:16AM CDT

GDXJ: 19.20 (+0.39), SAND: 2.40 (+0.05), FNV: 40.92 (+0.19), GDX: 13.72 (+0.15)

Pierre Lassonde: Gold At A Tipping Point; China Key To New Bull Market (Video)
Financial Sense - at Seeking Alpha - Sun Jun 07, 2:45AM CDT
By FS Staff Is the nearly four year bear market in gold finally coming to an end? Pierre Lassonde, Chairman of Franco-Nevada Corporation (NYSE: FNV ) and former Chairman of the World Gold Council, tells Financial Sense Newshour that gold is at a...
SGOL: 107.13 (+0.18), GTU: 38.05 (+0.08), OUNZ: 10.90 (unch), FNV: 40.92 (+0.19), GLD: 104.95 (+0.09), PHYS: 9.01 (+0.01), IAU: 10.58 (unch), AGOL: 107.80 (+1.20)

Dividend Champions For June 2015
David Fish - at Seeking Alpha - Sat May 30, 11:18PM CDT

AIN: 36.50 (+0.03), BBOX: 17.32 (-0.67), PRIM: 17.27 (+0.37), HNI: 48.59 (+0.29), POOL: 68.78 (+0.01), M: 68.75 (-1.20), GNTX: 16.07 (+0.27), LM: 47.73 (+0.40), HFC: 46.06 (+0.36), AWH: 42.16 (-0.59), POR: 34.67 (+0.49), LYB: 92.23 (+2.38), NSP: 49.75 (-0.32), BRS: 45.03 (+0.89), TRN: 28.38 (+0.07), FNV: 40.92 (+0.19), WAB: 99.15 (+1.22), MKSI: 35.36 (+0.13), EE: 35.48 (+0.13)

The Market Discounts True Gold Mining Shares
Christopher De Sousa - at Seeking Alpha - Wed May 27, 11:09AM CDT

SAND: 2.40 (+0.05), FNV: 40.92 (+0.19)

Pershimco Resources Is Undervalued And Just Secured An Investment From Agnico Eagle
Hard Asset Investments - at Seeking Alpha - Sat May 16, 4:33PM CDT

FNV: 40.92 (+0.19), RGLD: 50.58 (+0.40)

Franco-Nevada's (FNV) CEO David Harquail on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed May 13, 8:16PM CDT

FNV: 40.92 (+0.19)

Franco-Nevada Is A Money Machine
Value Sniper - at Seeking Alpha - Wed May 13, 12:49AM CDT

FNV: 40.92 (+0.19)

Franco Nevada Posts Solid Q1 Earnings And Increases Its Dividend: Is It Time To Buy?
Hard Asset Investments - at Seeking Alpha - Fri May 08, 9:01AM CDT

FNV: 40.92 (+0.19), SLW: 13.13 (+0.49), RGLD: 50.58 (+0.40)

Franco-Nevada Announces Election of Directors
PR Newswire - Thu May 07, 12:42PM CDT
Franco-Nevada Corporation (TSX: FNV; NYSE: FNV) announced that the nominees listed in the management proxy circular for the 2015 Annual and Special Meeting of Shareholders were elected as directors of the Corporation. Detailed results of the vote for the election of directors held at the Annual Meeting yesterday in Toronto are set out below.
FNV.TO: 52.91 (-0.15), FNV: 40.92 (+0.19)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 180

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Kulicke & Soffa Announces Conference Call for Fiscal Results

Updated Category News Views 122

Kulicke & Soffa Schedules Conference Call Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC), a leading name in semiconductor assembly technology, has announced a conference call to discuss its third fiscal quarter financial results and business outlook. The call is set for a future date, highlighting the company's commitment to transparency and communication with its...

Continue Reading
ARMOUR Residential REIT Launches Major Stock Offering for Growth

Updated Category News Views 162

ARMOUR Residential REIT Enters Public Stock Offering ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) has officially announced an underwritten public offering of 18,500,000 shares of common stock. The company is poised to grant underwriters an additional option to purchase up to 2,775,000 shares, making this a significant move for ARMOUR as it aims to enhance its...

Continue Reading
Celebrate Mother's Day with a Unique Brunch at Cannon + Belle

Updated Category News Views 195

Cannon + Belle Offers a Memorable Mother's Day Brunch Cannon + Belle at Hilton Austin is excited to announce an elevated Mother's Day brunch that promises to create unforgettable memories. This year, the restaurant will be hosting a special brunch event aimed at honoring mothers and all they do. With an impressive menu curated by the talented Chef Gereamy Cater, guests...

Continue Reading
Figma's Shares Surge in IPO But Valuation Remains a Concern

Updated Category News Views 244

Figma's Impressive IPO Performance Figma Inc. (NYSE: FIG) has captured significant investor attention following its explosive debut in the stock market. After launching its initial public offering, the company's shares skyrocketed by over 250%, marking a remarkable milestone for the firm. The stock began trading at a price of $33 per share, leading to approximately $1.2...

Continue Reading
Journey Medical Corporation's Emrosi Launch for Rosacea Relief

Updated Category News Views 215

Journey Medical Corporation Introduces Emrosi for Rosacea Treatment Journey Medical Corporation, a key player in the dermatological pharmaceutical industry, has recently launched Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), designed for the effective treatment of rosacea. The product, featuring a unique formulation of 10 mg immediate release and...

Continue Reading